In its essence, surveillance is the continuous gathering, analysis, and dissemination of data to those who need to know for the purposes of disease control. To understand the complications of new therapies, data concerning the type and number of complications (numerator) and the population at risk for complications (denominator) must be gathered. Information about the expected rates of complications among comparison populations must be known to place the observed rates into perspective. Such data may be developed through active or passive reporting systems, clinic-based surveillance, follow-up of sentinel events, and registries. An investigation of mortality among users of continuous subcutaneous insulin infusion (CSII) pumps is used as an example.
Skip Nav Destination
Article navigation
Articles|
September 01 1985
Surveillance of Acute Complications of New Therapies
Steven M Teutsch, M.D., M.P.H.;
Steven M Teutsch, M.D., M.P.H.
Division of Diabetes Control, Technology and Operational Research Branch, Center for Prevention Services, Centers for Disease Control
Atlanta, Georgia 30333
Search for other works by this author on:
William H Herman, M.D.
William H Herman, M.D.
Division of Diabetes Control, Technology and Operational Research Branch, Center for Prevention Services, Centers for Disease Control
Atlanta, Georgia 30333
Search for other works by this author on:
Address reprint requests to Steven M. Teutsch, M.D., at the above address.
Citation
Steven M Teutsch, William H Herman; Surveillance of Acute Complications of New Therapies. Diabetes Care 1 September 1985; 8 (Supplement_1): 51–53. https://doi.org/10.2337/diacare.8.1.S51
Download citation file:
21
Views